Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in parkinsonian mice

Journal of Neuroscience

Volumn 34, Issue 8, 2014, Pages 3090-3094

  Won, Lisa ^a   Ding, Yunmin ^a,b   Singh, Pardeep ^b   Kang, Un Jung ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Behavior; Cholinergic; Diphtheria toxin; Dyskinesia; Parkinson's disease; Striatum

Indexed keywords

BEHAVIOR; CHOLINERGIC; DIPHTHERIA TOXIN; DYSKINESIA; PARKINSON'S DISEASE; STRIATUM;

ADENOVIRIDAE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DENERVATION; DIPHTHERIA TOXIN; DNA, COMPLEMENTARY; DYSKINESIA, DRUG-INDUCED; HYDROXYDOPAMINES; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; LEVODOPA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOSTRIATUM; PARASYMPATHETIC NERVOUS SYSTEM; PARKINSONIAN DISORDERS;

EID: 84894076050     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2888-13.2014     Document Type: Article

References (35)

1. Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448-458. CrossRef Medline
2. Andersson M, Hilbertson A, Cenci MA (1999) Striatal fos B expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin m RNA in a rat model of Parkinson's disease. Neurobiol Dis 6:461-474. CrossRef Medline
3. Andersson M, Konradi C, Cenci MA (2001) cAMP response elementbinding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci 21: 9930-9943. Medline
4. Antipova V, Hawlitschka A, Mix E, Schmitt O, Dräger D, Benecke R, Wree A (2013) Behavioral and structural effects of unilateral intrastriatal injections of botulinum neurotoxin a in the rat model of Parkinson's disease. J Neurosci Res 91:838-847. CrossRef Medline
5. Birket-Smith E (1975) Abnormal involuntary movements in relation to anticholinergics and levodopa therapy. Acta Neurol Scand 52:158-160. CrossRef Medline
6. Bordia T, Campos C, McIntosh JM, Quik M (2010) Nicotinic receptormediated reduction in L-DOPA-induced dyskinesias may occur via desensitization. J Pharmacol Exp Ther 333:929-938. CrossRef Medline
7. Buck K, Ferger B (2010) L-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective. Drug Discov Today 15:867-875. CrossRef Medline
8. Calabresi P, Centonze D, Gubellini P, Pisani A, Bernardi G (2000) Acetylcholine-mediated modulation of striatal function. Trends Neurosci 23:120-126. CrossRef Medline
9. Chang JW, Wachtel SR, Young D, Kang UJ (1999) Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88:617-628. CrossRef Medline
10. Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R (2009) Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPAinduced dyskinesia and histone activation. Biol Psychiatry 66:603-613. CrossRef Medline
11. DeBoer P, Abercrombie ED, Heeringa M, Westerink BH (1993) Differential effect of systemic administration of bromocriptine and L-dopa on the release of acetylcholine from striatum of intact and 6-OHDA-treated rats. Brain Res 608:198-203. CrossRef Medline
12. Ding J, Peterson JD, Surmeier DJ (2008) Corticostriatal and thalamostriatal synapses have distinctive properties. J Neurosci 28:6483-6492. CrossRef Medline
13. Ding Y, Restrepo J, Won L, Hwang DY, Kim KS, Kang UJ (2007) Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. Neurobiol Dis 27:11-23. CrossRef Medline
14. Ding Y, Won L, Britt JP, Lim SA, McGehee DS, Kang UJ (2011) Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice. Proc Natl Acad Sci U S A 108:840-845. CrossRef Medline
15. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508. CrossRef Medline
16. Huang LZ, Campos C, Ly J, Ivy Carroll F, Quik M (2011) Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats. Neuropharmacology 60:861-868. CrossRef Medline
17. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2013) The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 65:171-222. CrossRef Medline
18. Jackson D, Abercrombie ED, Zigmond MJ (1993) Impact of L-dopa on striatal acetylcholine release: effects of 6-hydroxydopamine. J Pharmacol Exp Ther 267:912-918. Medline
19. Kalia LV, Brotchie JM, Fox SH (2013) Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Mov Disord 28:131-144. CrossRef Medline
20. Lees A (2005) Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 22:731-740. CrossRef Medline
21. Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) Amodel of L-DOPAinduced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16: 110-123. CrossRef Medline
22. Malmlöf T, Rylander D, Alken RG, Schneider F, Svensson TH, Cenci MA, Schilström B (2010) Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias. Exp Neurol 225:408-415. CrossRef Medline
23. 2 dopamine receptor-mediated modulation of voltage-dependent Na+channels reduces autonomous activity in striatal cholinergic interneurons. J Neurosci 24:10289-10301. CrossRef Medline
24. Oldenburg IA, Ding JB (2011) Cholinergic modulation of synaptic integration and dendritic excitability in the striatum. Curr Opin Neurobiol 21: 425-432. CrossRef Medline
25. Parikh V, Ji J, Decker MW, Sarter M (2010) Prefrontal beta2 subunitcontaining and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. J Neurosci 30:3518-3530. CrossRef Medline
26. Paxinos G, Franklin KBJ (1997) The mouse brain in stereotaxic coordinates. San Diego: Elsevier.
27. Picconi B, Centonze D, Håkansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6:501-506. CrossRef Medline
28. Pisani A, Bernardi G, Ding J, Surmeier DJ (2007) Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 30: 545-553. CrossRef Medline
29. Pourcher E, Bonnet AM, Kefalos J, Dubois B, Agid Y (1989) Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease. Mov Disord 4:195-201. CrossRef Medline
30. Putterman DB, Munhall AC, Kozell LB, Belknap JK, Johnson SW (2007) Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J Pharmacol Exp Ther 323:277-284. CrossRef Medline
31. Quik M, Campos C, Grady SR (2013) Multiple CNS nicotinic receptors mediate L-DOPA-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice. Biochem Pharmacol 86:1153-1162. CrossRef Medline
32. Traka M, Arasi K, Avila RL, Podojil JR, Christakos A, Miller SD, Soliven B, Popko B (2010) Agenetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination. Brain 133: 3017-3029. CrossRef Medline
33. Winkler C, Kirik D, Björklund A, Cenci MA (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10:165-186. CrossRef Medline
34. Witten IB, Lin SC, Brodsky M, Prakash R, Diester I, Anikeeva P, Gradinaru V, Ramakrishnan C, Deisseroth K (2010) Cholinergic interneurons control local circuit activity and cocaine conditioning. Science 330:1677-1681. CrossRef Medline
35. Zhang Y, Meredith GE, Mendoza-Elias N, Rademacher DJ, Tseng KY, Steece-Collier K (2013) Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses. J Neurosci 33:11655-11667. CrossRef Medline